Loading stock data…
argenx SE (ARGX)
$918.22-6.38 (-0.69%)
Market ClosedLast close Jul 24
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
argenx SE in the Healthcare sector is trading at $918.22 with a market capitalization of $54.8B. Wall Street consensus targets $1,079.39 (23 analysts), implying a +17.6% move over the next 12 months. The stock is currently near its 52-week high of $953.58, remaining 10.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.30B↑ | $1.29B↑ | $1.13B↑ | $947.96M↑ | $790.00M |
| Gross Profit | $1.18B↑ | $1.14B↑ | $1.02B↑ | $837.21M↑ | $709.00M |
| Operating Income | $394.00M↑ | $359.56M↑ | $349.97M↑ | $203.84M↑ | $139.00M |
| Net Income | $366.00M↓ | $532.95M↑ | $344.26M↑ | $245.36M↑ | $169.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and imm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.79B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.33%
Volume
Today's trading volume
311,578
Recent News
argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances
argenx SE (ARGNF) reports strong financial performance with a 60% year-over-year sales growth and strategic advancements in its treatment pipeline.
argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach
argenx delivered $1. 5 billion in second-quarter VYVGART product sales and entered the second half with two registrational study readouts expected before year-end.
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday
argenex Q2 Earnings Call Highlights
argenex (NASDAQ:ARGX) reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, as well as early momentum from a newly expanded label in generalized myasthenia gr
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts were climbing sharply higher late